New medical research out of the United Kingdom (UK) suggests using stem cell therapy to decrease tumor burden as a new possible treatment of malignant pleural mesothelioma.
From a March 19, 2014 news report, “Systemic stem cell therapy reduces malignant mesothelioma growth”:
Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma (MPM) cells and subsequently induce their death, according to preclinical study findings….
“Bone marrow-derived mesenchymal stem cells (MSCs) are attractive candidates as vectors for anticancer therapies for a variety of reasons,” say Sam Janes (University College London, UK) and colleagues who performed the study….
“In this study, we show for the first time that MSCs expressing TRAIL (MSCTRAIL) induce apoptosis in MPM cells in vitro,” Janes and team report in Thorax. TRAIL, or tumour necrosis factor-related apoptosis-inducing ligand, is a transmembrane protein and an “exciting anticancer molecule”, the team explains….
“MSCs home to and incorporate into tumours in vivo when delivered via both intrapleural and intravenous routes,” the team notes, so using these cells to deliver TRAIL is an interesting prospect for malignant mesothelioma, which is often too diffuse to surgically remove or does not respond well to chemotherapy.
We will continue to watch for more developments as regards the use of certain stem cells to reduce the growth of malignant pleural mesothelioma (MPM) cells.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.